Infant Mortality at 6 Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Women With Any Grade 3/4 Severe Adverse Event (Laboratory Only) · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
It is very uncertain whether mma Bana: AZT/3TC/LPV‐r changes women With Any Grade 3/4 Severe Adverse Event (Laboratory Only) compared with AZT/3TC/ABC (very low certainty).
1 finding from 1 review
Women With Any Severe Adverse Events Requiring Treatment Modification · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
It is very uncertain whether mma Bana: AZT/3TC/LPV‐r changes women With Any Severe Adverse Events Requiring Treatment Modification compared with AZT/3TC/ABC (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana: AZT/3TC/LPV‐r showed no clear difference in infants With Any Grade 3/4 Severe Adverse Events compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Prematurity · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana: AZT/3TC/LPV‐r may leads to higher prematurity compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
HIV Transmission or Death at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes infant HIV Transmission or Death at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Low birthweight · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana: AZT/3TC/LPV‐r showed no clear difference in infant Low Birth Weight compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Stillbirth · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Maternal death · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in maternal Mortality at Six Months compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Mother to Child Transmission In Utero Positive HIV DNA PCR Within 96 Hours · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission In Utero Positive HIV DNA PCR Within 96… compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Mother to Child Transmission Late Postpartum Negative HIV DNA PCR at Birth and One Month, But Positive HIV DNA PCR at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission Late Postpartum Negative HIV DNA PCR at… compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Weeks · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at Six Months Post‐Partum All Positive… compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
HIV‐Transmission or Death at 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes HIV‐Transmission or Death at 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes infant Grade 3/4 Severe Adverse Events at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Prematurity · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes prematurity compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).
1 finding from 1 review
Mother to Child Transmission at 1 Month · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at 1 Month compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission Cumulative by 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission Cumulative by 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Stillbirth · ART‐Eligible HIV‐infected Pregnant Women
It is very uncertain whether ekouevi: AZT/3TC/NVP changes stillbirths compared with other Short Course PMTCT Regimen (very low certainty).
1 finding from 1 review